On March 16th, Li Peng Research Group of Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences published the research results of PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells in the international academic journal OncoImmunology. The efficacy and specificity of CAR-PSCA and CAR-MUC1 chimeric antigen receptor T cells were verified in in vitro lung cancer cell lines and xenograft models derived from lung cancer patients.
Cancer immunotherapy has been ranked as one of the top ten scientific breakthroughs in 2013 by Science magazine and ranks first. In recent years, chimeric antigen receptor T cells (CAR-T cells) have been particularly effective in the treatment of leukemia such as B-ALL, and CAR-CD19 has entered the clinical trial stage. Therefore, the application of CAR-T cells in solid tumors is also closely followed.
On March 16th, Li Peng Research Group of Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences published the research results of PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells in the international academic journal OncoImmunology. The efficacy and specificity of CAR-PSCA and CAR-MUC1 chimeric antigen receptor T cells were verified in in vitro lung cancer cell lines and xenograft models derived from lung cancer patients.
The PDX model of NSCLC validates the killing effect of CAR-PSCA and CAR-MUC1 T
Li Peng's research team demonstrated the effectiveness and specificity of the CAR-T cell killing of the target PSCA and MUC1 antigens in the study group by killing lung cancer cell lines in vitro. Further, the research team constructed some primitive non-small-cell lung cancer (NSCLC) xenografted models (PDX), which proved that it is similar to the human pathological microenvironment. Sex. The study found that the PDX model can reconstruct the cell morphology and surface molecular markers of primary tumors.
Anesthesia Medical Co., Ltd. , https://www.jssinoanesthesias.com